Recent Finacing
Recent Raise
Tempest Therapeutics is a development-stage biotech developing small-molecule immuno-oncology therapies, including IDO inhibitor TPST-8844 (clinic-ready), PPARα antagonist TPST-1120, and EP receptor antagonists in collaboration with Inception Sciences.
